Which has higher valuation and earnings, QTTB or ENTX?

Q32 Bio has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 4.78 $29.82M $2.66 5.70 Entera Bio $40K 2,526.11 -$11.44M -$0.27 N/A

Is QTTB or ENTX more profitable?

Q32 Bio's return on equity of 149.23% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% Entera Bio N/A -83.31% -70.83%

Is ENTX or ELDN more profitable?

Entera Bio's return on equity of -83.31% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Eledon Pharmaceuticals N/A -116.97% -41.91%

Entera Bio (ENTX) Competitors

$2.05 -0.08 (-3.76%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.03 -0.02 (-1.12%)

As of 07/24/2026 07:34 PM Eastern

Compare

ENTX vs. FHTX, QTTB, LYEL, ELDN, and EDIT

Should you buy Entera Bio stock or one of its competitors? MarketBeat compares Entera Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entera Bio include Foghorn Therapeutics (FHTX), Q32 Bio (QTTB), Lyell Immunopharma (LYEL), Eledon Pharmaceuticals (ELDN), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.

How does Entera Bio compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Foghorn Therapeutics currently has a consensus price target of $11.43, indicating a potential upside of 135.64%. Entera Bio has a consensus price target of $9.00, indicating a potential upside of 339.02%. Given Entera Bio's higher possible upside, analysts plainly believe Entera Bio is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 1 articles in the media. Foghorn Therapeutics' average media sentiment score of 1.87 beat Entera Bio's score of 1.43 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Foghorn Therapeutics	Very Positive
Entera Bio	Positive

Entera Bio has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Entera Bio	N/A	-83.31%	-70.83%

Entera Bio has lower revenue, but higher earnings than Foghorn Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$28.22M	10.09	-$74.28M	-$1.16	N/A
Entera Bio	$40K	2,526.11	-$11.44M	-$0.27	N/A

Foghorn Therapeutics has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Entera Bio on 10 of the 16 factors compared between the two stocks.

How does Entera Bio compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Q32 Bio currently has a consensus target price of $22.33, indicating a potential upside of 47.41%. Entera Bio has a consensus target price of $9.00, indicating a potential upside of 339.02%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Q32 Bio has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Q32 Bio's return on equity of 149.23% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Entera Bio	N/A	-83.31%	-70.83%

Q32 Bio has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.78	$29.82M	$2.66	5.70
Entera Bio	$40K	2,526.11	-$11.44M	-$0.27	N/A

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Q32 Bio had 2 more articles in the media than Entera Bio. MarketBeat recorded 3 mentions for Q32 Bio and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.43 beat Q32 Bio's score of 0.91 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Q32 Bio	Positive
Entera Bio	Positive

Summary

Q32 Bio beats Entera Bio on 11 of the 15 factors compared between the two stocks.

How does Entera Bio compare to Lyell Immunopharma?

Lyell Immunopharma (NASDAQ:LYEL) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Entera Bio has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Entera Bio's return on equity of -83.31% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Entera Bio	N/A	-83.31%	-70.83%

Lyell Immunopharma presently has a consensus price target of $43.20, indicating a potential upside of 242.04%. Entera Bio has a consensus price target of $9.00, indicating a potential upside of 339.02%. Given Entera Bio's higher probable upside, analysts plainly believe Entera Bio is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lyell Immunopharma has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Entera Bio has higher revenue and earnings than Lyell Immunopharma. Entera Bio is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$31K	9,983.40	-$274.45M	-$13.80	N/A
Entera Bio	$40K	2,526.11	-$11.44M	-$0.27	N/A

In the previous week, Lyell Immunopharma had 1 more articles in the media than Entera Bio. MarketBeat recorded 2 mentions for Lyell Immunopharma and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.43 beat Lyell Immunopharma's score of 1.31 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Lyell Immunopharma	Positive
Entera Bio	Positive

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 10.6% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Entera Bio beats Lyell Immunopharma on 9 of the 17 factors compared between the two stocks.

How does Entera Bio compare to Eledon Pharmaceuticals?

Entera Bio (NASDAQ:ENTX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Entera Bio has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, Eledon Pharmaceuticals had 4 more articles in the media than Entera Bio. MarketBeat recorded 5 mentions for Eledon Pharmaceuticals and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.43 beat Eledon Pharmaceuticals' score of 0.57 indicating that Entera Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Entera Bio	Positive
Eledon Pharmaceuticals	Positive

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Entera Bio's return on equity of -83.31% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Entera Bio presently has a consensus price target of $9.00, indicating a potential upside of 339.02%. Eledon Pharmaceuticals has a consensus price target of $9.67, indicating a potential upside of 170.02%. Given Entera Bio's higher probable upside, analysts plainly believe Entera Bio is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Entera Bio has higher revenue and earnings than Eledon Pharmaceuticals. Entera Bio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	2,526.11	-$11.44M	-$0.27	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Summary

Entera Bio beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Entera Bio compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Entera Bio has lower revenue, but higher earnings than Editas Medicine. Entera Bio is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.28	-$160.06M	-$1.23	N/A
Entera Bio	$40K	2,526.11	-$11.44M	-$0.27	N/A

In the previous week, Editas Medicine had 2 more articles in the media than Entera Bio. MarketBeat recorded 3 mentions for Editas Medicine and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.43 beat Editas Medicine's score of 1.09 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Editas Medicine	Positive
Entera Bio	Positive

Editas Medicine currently has a consensus price target of $5.40, suggesting a potential upside of 107.69%. Entera Bio has a consensus price target of $9.00, suggesting a potential upside of 339.02%. Given Entera Bio's higher probable upside, analysts clearly believe Entera Bio is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Editas Medicine has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Entera Bio has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Entera Bio's return on equity of -83.31% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Entera Bio	N/A	-83.31%	-70.83%

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Editas Medicine and Entera Bio tied by winning 8 of the 16 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTX vs. The Competition

Export

Metric	Entera Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$104.99M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-7.59	21.48	27.14	23.64
Price / Sales	2,526.11	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	7.07	7.88	10.28	6.07
Net Income	-$11.44M	$23.86M	$3.60B	$331.99M
7 Day Performance	3.54%	-3.82%	-1.27%	-0.63%
1 Month Performance	41.38%	-2.61%	-0.37%	-2.00%
1 Year Performance	10.22%	32.79%	18.30%	13.62%

Entera Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTX Entera Bio	2.9125 of 5 stars	$2.05 -3.8%	$9.00 +339.0%	+7.3%	$104.99M	$40K	N/A	20	Positive News
FHTX Foghorn Therapeutics	3.4689 of 5 stars	$5.41 -0.6%	$11.43 +111.4%	-21.6%	$317.33M	$30.91M	N/A	120	Positive News
QTTB Q32 Bio	4.4811 of 5 stars	$18.55 -13.2%	$22.33 +20.4%	+555.8%	$314.59M	$53.74M	6.97	39	Short Interest Increase High Trading Volume
LYEL Lyell Immunopharma	3.4193 of 5 stars	$13.45 -6.2%	$43.00 +219.8%	+21.3%	$313.74M	$40K	N/A	270	Positive News Analyst Forecast
ELDN Eledon Pharmaceuticals	2.5545 of 5 stars	$4.02 +4.2%	$9.67 +140.2%	-4.0%	$310.61M	N/A	N/A	10	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entera Bio (ENTX) Competitors

ENTX vs. FHTX, QTTB, LYEL, ELDN, and EDIT

How does Entera Bio compare to Foghorn Therapeutics?

Summary

How does Entera Bio compare to Q32 Bio?

Summary

How does Entera Bio compare to Lyell Immunopharma?

Summary

How does Entera Bio compare to Eledon Pharmaceuticals?

Summary

How does Entera Bio compare to Editas Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entera Bio (ENTX) Competitors

ENTX vs. FHTX, QTTB, LYEL, ELDN, and EDIT

How does Entera Bio compare to Foghorn Therapeutics?

Do analysts prefer FHTX or ENTX?

Do institutionals & insiders believe in FHTX or ENTX?

Does the media prefer FHTX or ENTX?

Is FHTX or ENTX more profitable?

Which has stronger valuation & earnings, FHTX or ENTX?

Which has more risk and volatility, FHTX or ENTX?

Summary

How does Entera Bio compare to Q32 Bio?

Do analysts rate QTTB or ENTX?

Which has more risk & volatility, QTTB or ENTX?

Is QTTB or ENTX more profitable?

Which has higher valuation and earnings, QTTB or ENTX?

Do insiders and institutionals have more ownership in QTTB or ENTX?

Does the media favor QTTB or ENTX?

Summary

How does Entera Bio compare to Lyell Immunopharma?

Is LYEL or ENTX more profitable?

Do analysts rate LYEL or ENTX?

Which has more risk and volatility, LYEL or ENTX?

Which has preferable earnings & valuation, LYEL or ENTX?

Does the media favor LYEL or ENTX?

Do insiders & institutionals have more ownership in LYEL or ENTX?

Summary

How does Entera Bio compare to Eledon Pharmaceuticals?

Which has more volatility and risk, ENTX or ELDN?

Does the media prefer ENTX or ELDN?

Do insiders and institutionals believe in ENTX or ELDN?

Is ENTX or ELDN more profitable?

Do analysts recommend ENTX or ELDN?

Which has higher valuation & earnings, ENTX or ELDN?

Summary

How does Entera Bio compare to Editas Medicine?

Which has stronger earnings and valuation, EDIT or ENTX?

Does the media refer more to EDIT or ENTX?

Do analysts rate EDIT or ENTX?

Which has more volatility and risk, EDIT or ENTX?

Is EDIT or ENTX more profitable?

Do insiders & institutionals believe in EDIT or ENTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools